Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

24 maj 2016 uppdaterad av: Blaze Bioscience Inc.

A Phase 1 Study of BLZ-100 Administered by Intravenous Injection in Subjects With Soft Tissue Sarcoma Undergoing Surgery

Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue, and failure to surgically remove a cancer-affected lymph node or residual cancer at the surgical margin reduces a patient's chance of survival. Moreover, damage to adjacent normal tissue during surgery can result in significant morbidity. The investigators hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as they operate. This is a safety study to assess the safety of BLZ-100 in patients with soft tissue sarcoma undergoing surgery.

Studieöversikt

Status

Indragen

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Subjects who provide voluntary written informed consent will be screened for eligibility. Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to participate.

This is a two part study:

Part 1 - Dose Finding: Subjects will be required to arrive at the phase 1 unit for dosing 2-3 days prior to the planned surgical excision. Two dose levels of BLZ-100 (3 mg and 12 mg) will be evaluated in a total of 6 subjects with a 2-3 day post-dose imaging interval (also defined as the Intermediate Imaging interval).

Part 2 - Imaging Interval Assessment: The BLZ-100 dose to be evaluated in Part 2 will be determined by the Protocol Steering Committee following completion of Part 1. In Part 2, up to 15 additional subjects will be randomized into one of three imaging interval groups (up to 6 subjects per group): Early Imaging (within 1 day post BLZ-100 dose), Intermediate Imaging (2-3 days post BLZ-100 dose), and Late Imaging (4-7 days post BLZ-100 dose). Subjects will be required to arrive at the phase 1 unit for dosing between 1 and 7 days prior to planned surgical excision, depending on which imaging interval they are randomized to.

Following dosing, all subjects will be monitored for safety.

Studietyp

Interventionell

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Förenta staterna
    • California
      • Los Angeles, California, Förenta staterna, 90048
        • Cedars-Sinai Medical Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Male of female subject aged 18-75 years
  2. Diagnosis of soft tissue sarcoma, with scheduled surgical removal for treatment for the disease and completion of chemotherapy or radiation within 4 weeks of BLZ-100 administration
  3. Able to provide written informed consent
  4. If of child-bearing potential, agree to continued use of two reliable methods of contraceptive from study entry (time of informed consent) through 30 days after BLZ-100 administration
  5. Available for all study visits and able to comply with all study requirements

Exclusion Criteria:

  1. Clinically-suspected and/or pathologically-confirmed sarcoma of the bone (e.g. osteosarcoma, Ewing's sarcoma with bony involvement, chondrosarcoma, Kaposi's sarcoma, extraosseous primitive neuroectodermal tumor [PNET])
  2. Evidence of metastatic disease
  3. Female who is lactating/breastfeeding
  4. Female with a positive pregnancy test or who is planning to become pregnant during the duration of the study
  5. Karnofsky Performance Status of <60%

  6. Any of the following laboratory abnormalities at Screening:

    • Neutrophil count <1.5 x 10^9/L
    • Platelets <75 x 10^9/L
    • Hemoglobin <10 g/dL (may be determined following transfusion)
    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3x upper limit of normal (ULN)
    • Total bilirubin >1.5x upper limit of reference range (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction)
    • Internal Normalized Ratio (INR) >1.5
    • Creatinine >1.5x ULN
    • Calculated estimated glomerular filtration rate (eGFR) ≤60 mL/min
  7. Positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)
  8. QTc prolongation >450 msec
  9. History of hypersensitivity or allergic reactions requiring corticosteroids, epinephrine, and/or hospitalization
  10. Uncontrolled asthma or asthma requiring oral corticosteroids
  11. Known or suspected sensitivity to imaging agents that may be used in clinical assessment of this study
  12. Known or suspected sensitivity to indocyanine green (ICG)
  13. Unstable angina, myocardial infarction, known or suspected transient ischemic events, or stroke within 24 weeks of start of Screening
  14. Uncontrolled hypertension
  15. Initiation of new photosensitizing drugs within 30 days of Screening
  16. Use of any ongoing medications, which might generate fluorescence or, according to the medication label, might generate a photochemical reaction. These include haematoporphyrin derivatives and purified fractions, Photofrin®, and the precursors of protoporphyrin IX (5-Aminolevulinic acid) used in Gliolan or Hexvix
  17. Receipt of an investigational drug or device within 30 days of enrollment
  18. Prior administration of BLZ-100
  19. Any concurrent condition, including psychological and social situations, which, in the opinion of the investigator, would adversely impact the subject or the interpretation of the study data

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: BLZ-100

All participants in the study will receive the investigational drug product BLZ-100.

In part 1 of the study, two dose levels of BLZ-100 will be evaluated (3 mg and 12 mg) in 6 subjects, with a 2-3 post-dose imaging window.

In part 2 of the study up to 15 additional subjects will be randomized to one of three imaging interval groups (up to 6 subjects/interval): Early Imaging (within 1 day post-BLZ-100 dose), Intermediate Imaging (2 - 3 days post- BLZ-100 dose), and Late Imaging (4 - 7 days post- BLZ-100 dose).
Läkemedel: BLZ-100

All subjects enrolled in the study will receive doses of BLZ-100, an investigational drug for imaging tumors.

Three different imaging windows will be investigated during the study:

Early Imaging (imaging occurs within 1 day post-BLZ-100 dose); Intermediate Imaging (imaging occurs within 2-3 days post-BLZ-100 dose); Late Imaging (imaging occurs 4-7 post-BLZ-100 dose)

All subjects in Part 1 of the study will be imaged in the Intermediate Imaging group. Subjects in Part 2 of the study will be randomized into one of the three imaging groups.

Andra namn:
  • Tumörfärg

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Antal deltagare med biverkningar
Tidsram: Sju dagar efter administrering av studieläkemedlet
Säkerheten kommer att bedömas genom fysisk undersökning och mätning av vitala tecken och laboratoriesäkerhetsparametrar.
Sju dagar efter administrering av studieläkemedlet

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change of concentration of BLZ-100 in the blood
Tidsram: Prior to dosing and at 1 minute, 5 minutes, 15 minutes, 30 minutes, 60 minutes and 120 minutes after end of injection, and pre-surgery and 24 hours post-surgery
BLZ-100 levels in blood will be analyzed by chemical means and these data will be used to calculate pharmacokinetic parameters.
Prior to dosing and at 1 minute, 5 minutes, 15 minutes, 30 minutes, 60 minutes and 120 minutes after end of injection, and pre-surgery and 24 hours post-surgery
Fluorescence signal from areas of tumor and non-tumor
Tidsram: 1 day post-dose, 2-3 days post-dose, or 3-7 days post-dose
Fluorescent signal in sections of excised tumor and adjacent normal tissue will be measured using an infrared imaging system.
1 day post-dose, 2-3 days post-dose, or 3-7 days post-dose
Ideal combination of dose and imaging interval
Tidsram: 1 day post-dose, 2-3 days post-dose, 3-7 days post-dose
Fluorescent signal will be evaluated in sections of excised tumor and adjacent normal tissue to determine which imaging interval provides the optimal images.
1 day post-dose, 2-3 days post-dose, 3-7 days post-dose

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Blaze Bioscience Inc.

Samarbetspartners

National Cancer Institute (NCI)

Utredare

  • Huvudutredare: Charles Forscher, MD, Cedars-Sinai Medical Center

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 september 2015

Primärt slutförande (Faktisk)

1 maj 2016

Avslutad studie (Faktisk)

1 maj 2016

Studieregistreringsdatum

Först inskickad

2 juni 2015

Först inskickad som uppfyllde QC-kriterierna

4 juni 2015

Första postat (Uppskatta)

8 juni 2015

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

26 maj 2016

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

24 maj 2016

Senast verifierad

1 maj 2016

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • BB-003
  • 261201400046C-0-0-1 (U.S.S. NIH-anslag/kontrakt)

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Sarkom, mjuk vävnad

Kliniska prövningar på BLZ-100

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Montenegro

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

Prenumerera